Oscar Health (OSCR) Stock May Be Undervalued Despite Raised Guidance

Oscar Health has been on a powerful run, and the stock’s sharp repricing now puts a spotlight on a simple issue for investors: whether the current market value lines up with what its earnings can support. With that kind of shift in expectations already in the price, the key question becomes what the recent earnings story really justifies.

• Over the past 3 years the share price has returned about 3.9x, which puts a lot of weight on whether Oscar Health’s earnings profile can keep backing up that kind of move.
• Management’s turnaround efforts, including raising full year earnings from operations expectations and growing membership to 2.96 million, may support different assumptions about profitability and capital needs than investors used a few years ago.
• Your read on Oscar Health is one view; the desks covering it have another. See what analysts think Oscar Health's shares could be worth.

The stock’s next move may depend on whether Oscar Health’s current earnings are strong and durable enough to justify today’s price.

If you want to test the same earnings versus price question that Oscar Health now faces across a broader set of companies, start with 42 high quality undervalued stocks.

Does Oscar Health Look Undervalued on Earnings?

The P/E ratio suits Oscar Health because earnings are now the main driver investors are using to anchor the story. On that score, the stock trades on about 18.6x earnings, which is above the Insurance sector average of roughly 12.0x but below the peer group at about 36.0x. Because the current multiple sits under what a tailored fair-value model suggests for a business with Oscar Health’s risk profile and economics, the shares screen as undervalued on this framework.

Because management lifted its earnings from operations guidance earlier in 2026, the market is already paying a premium to the broad industry. Yet the P/E still implies a discount to similar insurers and to what the model flags as a fairer level. For anyone weighing Oscar Health today, the key judgment is whether those earnings are sustainable enough that this discounted P/E relative to peers and the tailored benchmark offers sufficient compensation for the capital and regulatory risks involved. Explore the numbers behind Oscar Health's P/E valuation.

The Oscar Health Narrative: What Would Justify Today's Price?

Narratives pick up where Oscar Health's valuation puzzle leaves off by spelling out which assumptions on future growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today's price on Simply Wall St's Community page. Each one moves beyond a single P/E or model output and instead lays out the key drivers behind its fair value view so you can compare those assumptions with the actual numbers as they come through over time.

Oscar Health splits the community, with one side seeing a deep discount and the other arguing expectations already stretch the earnings story.

Bull case: 94% undervalued

"The market is mispricing this asset by an order of magnitude..."

Discover why this Narrative puts Oscar Health at 94% undervalued.

Bear case: 23% overvalued

"The current numbers and guidance, including a P/E above the insurance sector average and long-term EPS targets, imply that Oscar Health shares already price in successful delivery of its ACA growth, CHOICE expansion and capital generation plans..."

Explore why this Narrative puts Oscar Health at 23% overvalued.

One more Oscar Health check that belongs next to the earnings and P/E story

There is one piece of the Oscar Health picture that price ratios cannot capture. It is the recent selling activity by company insiders and what those trades might signal for you as a shareholder. See the recent insider selling flagged for Oscar Health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com